SBRT 2016

Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials Chang Lancet Oncol 2015 Discussion of this study: Opponent Supporter Only 58 centers Two high quality studies Overall 38 centres Best of-ist-time Tx in both studies Differences in study design Interpretation considering statistical limitations Surgical OS 67% in STARS and 100% in ROSEL Best evidence available until today  SBRT is better tolerated treatment resulting is most likely identical overall survival  Higher toxicity versus higher rates of locoreginal recurrence

/ Matthias Guckenberger - SBRT for stage I NSCLC

51